Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Popped Today

By Prosper Junior Bakiny – May 8, 2020 at 4:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna continues to post staggering gains because of its efforts to develop a vaccine for the coronavirus.

What happened?

Shares of the clinical-stage biotech company Moderna (MRNA -0.10%) closed up 10.9% on Friday. There was no company-specific news that served as the catalyst for Moderna's shares rising today, but investors remain optimistic that the company will win the race to develop a vaccine for the coronavirus.

As a result of its efforts to develop a vaccine for COVID-19, Moderna's stock has been rising all year, and today's gains are likely a continuation of that trend. 

So what

Moderna's shares jumped yesterday after the company announced that its Investigational New Drug (IND) application for mRNA-1273 -- Moderna's potential vaccine for COVID1-19 -- was approved by the U.S. Food and Drug Administration (FDA). Moderna can now move forward with a phase 2 study for mRNA-1273, which the company said should begin "shortly." Moderna is also planning on initiating a phase 3 study in early summer.

Nurse holding test tube with blood for coronavirus testing.

Image Source: Getty Images.

With Moderna racing through the early phases of the development of its investigational vaccine for the novel coronavirus, investors keep loading up on shares of the biotech company and continue to drive its stock price higher. Moderna's stock is now up by 202.7% year to date, and the company's shares are at an all-time high. Note that the S&P 500 is down by 9.3% since the year started. 

Now what

Moderna will likely continue to outpace the broader market, at least as long as the company is perceived as one of the leaders in the hunt for a COVID-19 vaccine. However, investors thinking of buying shares of this biotech company should remember that there are dozens of potential COVID-19 vaccines currently being developed

And while Moderna is giving off the impression of having left most of its competitors in the dust, the company still has a long way to go before it can hope to launch mRNA-1273 on the market. Until then, a lot could happen to cause Moderna's stock to fall off a cliff. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$122.11 (-0.10%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.